Wanbury Limited's facilities in Tanuku and Patalganga have successfully passed inspections by Australia's TGA and Korea's MFDS, respectively. This paves the way for increased exports to Australia and strengthens the company's global compliance standing.

Wanbury Limited Secures Key International Regulatory Approvals

Wanbury Limited's Tanuku facility has successfully passed a quality inspection by Australia's Therapeutic Goods Administration (TGA). Concurrently, its Patalganga site has received a GMP certificate from the MFDS (Korean FDA) following an April 2026 inspection.

Reader Takeaway: Successful international inspections boost export potential; watch for formal certificate issuance.

What just happened

Wanbury Limited announced that its manufacturing facility in Tanuku, Andhra Pradesh, has completed a quality inspection by the TGA of Australia. Additionally, the company secured a GMP certificate for its Patalganga facility from the MFDS (Korean FDA).

Why this matters

Passing these rigorous international regulatory inspections is crucial for API manufacturers. It enhances market access to regulated markets like Australia, which typically offer better pricing and stable demand. The Korean GMP certificate further solidifies the company's compliance credentials globally.

The backstory

Wanbury Limited is an established player in the pharmaceutical ingredients sector. The company has been focusing on expanding its international footprint and ensuring its manufacturing practices meet global standards. Achieving compliance with authorities like the TGA and MFDS is a significant milestone for any pharmaceutical exporter.

What changes now

With the successful TGA inspection at the Tanuku site, Wanbury is set to export three additional Active Pharmaceutical Ingredients (APIs) to Australia, pending the formal GMP certificate issuance. The MFDS certification for the Patalganga site validates its manufacturing standards for the Korean market.

Risks to watch

The primary risk is the final issuance of the TGA GMP certificate for the Tanuku facility, which is a prerequisite for commencing exports of the three new APIs to Australia. Any delays or unforeseen issues in this final step could impact the anticipated export growth.

Peer comparison

Many Indian pharmaceutical companies are actively seeking approvals from international regulatory bodies like the TGA and FDA to enhance their export capabilities. Wanbury's success places it in a competitive position to leverage these opportunities, similar to peers focusing on regulatory compliance for market expansion.

Context metrics

The inspections were conducted by the TGA (Australia) and MFDS (Korea). The Patalganga inspection occurred in April 2026.

What to track next

Investors should closely monitor the formal issuance of the TGA GMP certificate for the Tanuku facility and any subsequent export orders from Australia. Tracking any new product approvals or market entries based on these certifications will also be key.